Drugs / Fluzone High-Dose Quadrivalent
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03698279 | Oct 2018 → Oct 2019 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05050318 | Sep → Nov 2021 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT05007041 Comparator | Sep 2021 → Mar 2023 | — | Duke University | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-10-07 | Sanofi | Results Sanofi: Positive results from the first study of high-dose influenza vaccine with a COVID-19 mRNA booster support co-administration recommendations sanofi.com ↗
This is the first study to provide supportive evidence for vaccinating against influenza at the same time as a COVID-19 mRNA booster in seniors. |
All press releases naming this drug 2 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluzone High-Dose Quadrivalent | “Quadrivalent high-dose inactivated influenza vaccine (Fluzone® High-Dose Quadrivalent, IIV4-HD) was licensed in the USA in 2019 for adults ≥ 65 years of age.” PMID 33610374 ↗ Feb 2021 |
| Known as | IIV4-HD | “Quadrivalent high-dose inactivated influenza vaccine (Fluzone® High-Dose Quadrivalent, IIV4-HD) was licensed in the USA in 2019 for adults ≥ 65 years of age.” PMID 33610374 ↗ Feb 2021 |
| Modality | Vaccine | “Quadrivalent high-dose inactivated influenza vaccine” PMID 33610374 ↗ Feb 2021 |
| Route | Intramuscular | “received 1 or 2 doses intramuscularly” PMID 33610374 ↗ Feb 2021 |